Claims for Patent: 11,142,528

Summary for Patent: 11,142,528

Title:	Substituted pyrazolo[1,5-a]pyrimidines as Bruton's tyrosine kinase modulators
Abstract:	The invention is fused heterocyclic compounds of formula (I), and salts thereof, compositions thereof, and methods of use therefor. In particular, disclosed herein are certain fused heterocyclic compounds that can be useful for inhibiting protein kinase, including Bruton's tyrosine kinase (Btk), and for treating disorders mediated thereby. ##STR00001##
Inventor(s):	Wang; Zhiwei (Beijing, CN), Guo; Yunhang (Beijing, CN)
Assignee:	BEIGENE SWITZERLAND GMBH (Basel, CH)
Application Number:	16/739,447
Patent Claims:	1. An oral dosage form comprising a pharmaceutically acceptable carrier and a compound of formula I: ##STR00578## or a pharmaceutically acceptable salt or stereoisomer thereof, wherein: A is a 5- or 6-membered aromatic ring, wherein the 5- or 6-membered aromatic ring comprises 0, 1, 2, or 3 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur; L is a bond, --CH.sub.2--, --NR.sup.12--, --O--, or --S--; R.sup.1 is H, halogen, CN, alkyl, heteroalkyl, alkenyl, alkynyl, C(NR.sup.13)NR.sup.14R.sup.15, C(O)R.sup.13, C(O)NR.sup.13R.sup.14, C(O)OR.sup.13, NR.sup.13R.sup.14, NR.sup.13C(O)R.sup.14, NR.sup.13C(O)NR.sup.14R.sup.15, NR.sup.13C(O)OR.sup.14, NR.sup.13S(O).sub.2R.sup.14, NR.sup.13S(O).sub.2NR.sup.14R.sup.15, OR.sup.13, S(O).sub.2R.sup.13, cycloalkyl, heterocyclyl, aryl, or heteroaryl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more independently selected R.sup.16 substituents; each R.sup.2 is independently halogen, CN, alkyl, C(NR.sup.13)NR.sup.14R.sup.15, C(O)R.sup.13, C(O)NR.sup.13R.sup.14, C(O)OR.sup.13, NR.sup.13R.sup.14, NR.sup.13C(O)R.sup.14, NR.sup.13C(O)NR.sup.14R.sup.15, NR.sup.13C(O)OR.sup.14, NR.sup.13S(O).sub.2R.sup.14, NR.sup.13S(O).sub.2NR.sup.14R.sup.15, OR.sup.13, S-alkyl, or S(O).sub.2R.sup.13; R.sup.4 is H, halogen, CN, alkyl, heteroalkyl, alkenyl, alkynyl, C(NR.sup.13)NR.sup.14R.sup.15, C(O)R.sup.13, C(O)NR.sup.13R.sup.14, C(O)OR.sup.13, NR.sup.13R.sup.14, NR.sup.13C(O)R.sup.14, NR.sup.13C(O)NR.sup.14R.sup.15, NR.sup.13C(O)OR.sup.14, NR.sup.13S(O).sub.2R.sup.14, NR.sup.13S(O).sub.2NR.sup.14R.sup.15, OR.sup.13, S(O).sub.2R.sup.13, cycloalkyl, heterocyclyl, aryl, or heteroaryl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more independently selected R.sup.16 substituents; R.sup.5 is H, halogen, CN, alkyl, heteroalkyl, alkenyl, alkynyl, C(NR.sup.13)NR.sup.14R.sup.15, C(O)R.sup.13, C(O)NR.sup.13R.sup.14, C(O)OR.sup.13, NR.sup.13R.sup.14, NR.sup.13C(O)R.sup.14, NR.sup.13C(O)NR.sup.14R.sup.15, NR.sup.13C(O)OR.sup.14, NR.sup.13S(O).sub.2R.sup.14, NR.sup.13S(O).sub.2NR.sup.14R.sup.15, OR.sup.13, S(O).sub.2R.sup.13, cycloalkyl, heterocyclyl, aryl, or heteroaryl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more independently selected R.sup.16 substituents; R.sup.6 is H, halogen, CN, alkyl, heteroalkyl, alkenyl, alkynyl, C(NR.sup.13)NR.sup.14R.sup.15, C(O)R.sup.13, C(O)NR.sup.13R.sup.14, C(O)OR.sup.13, NR.sup.13R.sup.14, NR.sup.13C(O)R.sup.14, NR.sup.13C(O)NR.sup.14R.sup.15, NR.sup.13C(O)OR.sup.14, NR.sup.13S(O).sub.2R.sup.14, NR.sup.13S(O).sub.2NR.sup.14R.sup.15, OR.sup.13, S(O).sub.2R.sup.13, cycloalkyl, heterocyclyl, aryl, or heteroaryl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more independently selected R.sup.16 substituents; R.sup.7 is H, halogen, CN, alkyl, heteroalkyl, alkenyl, alkynyl, C(NR.sup.13)NR.sup.14R.sup.15, C(O)R.sup.13, C(O)NR.sup.13R.sup.14, C(O)OR.sup.13, NR.sup.13R.sup.14, NR.sup.13C(O)R.sup.14, NR.sup.13C(O)NR.sup.14R.sup.15, NR.sup.13C(O)OR.sup.14, NR.sup.13S(O).sub.2R.sup.14, NR.sup.13S(O).sub.2NR.sup.14R.sup.15, OR.sup.13, S(O).sub.2R.sup.13, cycloalkyl, heterocyclyl, aryl, or heteroaryl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more independently selected R.sup.16 substituents; R.sup.12 is H or lower alkyl; each R.sup.13 is independently H, alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl; each R.sup.14 is independently H, alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl; each R.sup.15 is independently H, alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl; or each R.sup.13 and R.sup.14, together with the atom(s) to which they are attached, independently forms a cycloalkyl, heterocyclyl, aryl, or heteroaryl, wherein each cycloalkyl, heterocyclyl, aryl, or heteroaryl is optionally and independently substituted with one or more independently selected R.sup.16 substituents; or each R.sup.14 and R.sup.15, together with the atom(s) to which they are attached, independently forms a cycloalkyl, heterocyclyl, aryl, or heteroaryl, wherein each cycloalkyl, heterocyclyl, aryl, or heteroaryl is optionally and independently substituted with one or more independently selected R.sup.16 substituents; each R.sup.16 is independently halogen, CN, oxo, alkyl, alkenyl, alkynyl, C(NR')NR''R''', C(O)R', C(O)NR'R'', C(O)OR', NR'R'', NR'C(O)R'', NR'C(O)NR'R'', NR'C(O)OR'', NR'S(O).sub.2R'', NR'S(O).sub.2NR''R''', OR', S(O).sub.2R', S(O).sub.2aryl, cycloalkyl, heterocyclyl, aryl, or heteroaryl; each R' is independently H, halogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl; each R'' is independently H, halogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl; each R''' is independently H, halogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl; or each R' and R'', together with the atom(s) to which they are attached, independently forms a cycloalkyl, heterocyclyl, aryl, or heteroaryl; or each R'' and R''', together with the atom(s) to which they are attached, independently forms a cycloalkyl, heterocyclyl, aryl, or heteroaryl; W is --CH.sub.2-- or --C(O)--; m is 1; n is 0, 1, 2, 3, or 4; p is 1; and -- is a single or double bond; wherein each alkyl, alkenyl, and alkynyl of each R.sup.16, R', R'', and R''' is optionally and independently substituted with one or more substituents independently selected from the group consisting of halogen, CN, oxo, C(NR.sup.a)NR.sup.bR.sup.c, C(O)R.sup.a, C(O)NR.sup.aR.sup.b, C(O)OR.sup.a, NR.sup.aR.sup.b, NR.sup.aC(O)R.sup.b, NR.sup.aC(O)NR.sup.aR.sup.b, NR.sup.aC(O)OR.sup.b, NR.sup.aS(O).sub.2R.sup.b, NR.sup.aS(O).sub.2NR.sup.bR.sup.c, OR.sup.a, S(O).sub.2R.sup.a, S(O).sub.2aryl, cycloalkyl, heterocyclyl, aryl, and heteroaryl; wherein each cycloalkyl, heterocyclyl, aryl, and heteroaryl of each R.sup.16, R', R'', and R''' is optionally and independently substituted with one or more substituents independently selected from the group consisting of halogen, CN, oxo, alkyl, alkenyl, alkynyl, C(NR.sup.a)NR.sup.bR.sup.c, C(O)R.sup.a, C(O)NR.sup.aR.sup.b, C(O)OR.sup.a, NR.sup.aR.sup.b, NR.sup.aC(O)R.sup.b, NR.sup.aC(O)NR.sup.aR.sup.b, NR.sup.aC(O)OR.sup.b, NR.sup.aS(O).sub.2R.sup.b, NR.sup.aS(O).sub.2NR.sup.bR.sup.c, OR.sup.a, S(O).sub.2R.sup.a, S(O).sub.2aryl, cycloalkyl, heterocyclyl, aryl, and heteroaryl; and wherein each R.sup.a, R.sup.b, and R.sup.c is independently H, halogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl; with the proviso that when .dbd. is a double bond, R.sup.5 and R.sup.7 are absent. 2. The oral dosage form of claim 1, wherein the oral dosage form comprises 10 mg to 500 mg of the compound of formula I, or a pharmaceutically acceptable salt or stereoisomer thereof. 3. The oral dosage form of claim 1, wherein the oral dosage form comprises 20 mg to 500 mg of the compound of formula I, or a pharmaceutically acceptable salt or stereoisomer thereof. 4. The oral dosage form of claim 1, wherein the oral dosage form is a tablet or a capsule. 5. The oral dosage form of claim 1, wherein A is phenyl. 6. The oral dosage form of claim 1, wherein L is --O--. 7. The oral dosage form of claim 1, wherein R.sup.1 is aryl, wherein the aryl is optionally substituted with one or more independently selected R.sup.16 substituents. 8. The oral dosage form of claim 1, wherein: each R.sup.2 is independently halogen, lower alkyl, or lower OR.sup.13; and each R.sup.13 is independently alkyl. 9. The oral dosage form of claim 1, wherein R.sup.4 is ##STR00579## 10. The oral dosage form of claim 1, wherein R.sup.4 is: ##STR00580## 11. The oral dosage form of claim 1, wherein: R.sup.5 is H; R.sup.6 is H; and R.sup.7 is H. 12. The oral dosage form of claim 1, wherein W is --CH.sub.2--. 13. The oral dosage form of claim 1, wherein -- is a single bond. 14. The oral dosage form of claim 1, wherein the compound is of formula II: ##STR00581## or a pharmaceutically acceptable salt or stereoisomer thereof. 15. The oral dosage form of claim 1, wherein the compound is: ##STR00582## or a pharmaceutically acceptable salt or stereoisomer thereof. 16. The oral dosage form of claim 1, wherein the compound, or stereoisomer thereof, is: ##STR00583## or a pharmaceutically acceptable salt thereof. 17. The oral dosage form of claim 1, wherein the compound, or stereoisomer thereof, is: ##STR00584## or a pharmaceutically acceptable salt thereof. 18. A method for modulating Bruton's tyrosine kinase activity in a subject, comprising administering to the subject in need thereof a therapeutically effective amount of the oral dosage form of claim 1. 19. The method of claim 18, wherein the subject has a B-cell proliferative disorder selected from the group consisting of chronic lymphocytic leukemia, chronic lymphocytic lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, and non-Hodgkin's lymphoma.